RESULTS The global antihypertensive activity of ARB differs from that observed with amlodipine in the sense that the magnitude of the reduction in the BP values does not essentially depend on the initial BP values nor on the dose used .
When only ARB were considered , the drug used was a determinant for systolic BP reduction , whereas for diastolic BP the influence was on the BP reduction and the duration of the antihypertensive activity .
The dose used had a particular influence on the duration of the antihypertensive activity for both systolic and diastolic BP .
CONCLUSION Among the ARB , the influence is on duration more than on the magnitude of BP reduction .
Dose , therefore , is an important factor in the duration of antihypertensive activity
OBJECTIVE To perform a systematic review of the antihypertensive activity of the angiotensin II AT1 receptor antagonists ( ARB ) .
Antihypertensive efficacy of olmesartan medoxomil, a new angiotensin II receptor antagonist, as assessed by ambulatory blood pressure measurements.
Olmesartan medoxomil is a new angiotensin II receptor blocker . In this r and omized , double-blind , placebo-controlled study , the efficacy and safety of olmesartan medoxomil was assessed in 334 patients with moderate to severe essential hypertension . Patients were r and omized to receive placebo ; 5 , 20 , or 80 mg olmesartan medoxomil q.d . ; or 2.5 , 10 , or 40 mg olmesartan medoxomil b.i.d . Ambulatory and cuff blood pressure were measured prior to and after 8 weeks of treatment . Treatment with olmesartan medoxomil result ed in a significant placebo-adjusted reduction of mean 24-hour ambulatory diastolic blood pressure of 9.6 mm Hg , 12.2 mm Hg , and 10.6 mm Hg in the 5- , 20- , and 80-mg q.d . groups , respectively . Corresponding reductions in mean ambulatory systolic blood pressure were 14.5 mm Hg , 16.5 mm Hg , and 15.4 mm Hg . Similar reductions of diastolic and systolic blood pressure were seen with b.i.d . dosing . The diastolic trough-to-peak ratios of the q.d . doses of olmesartan medoxomil ranged from 57%-70 % , indicating 24-hour effectiveness . The safety profile of olmesartan medoxomil was similar to that of placebo . Olmesartan medoxomil appears to be a safe and effective once-a-day treatment for hypertension
RESULTS The global antihypertensive activity of ARB differs from that observed with amlodipine in the sense that the magnitude of the reduction in the BP values does not essentially depend on the initial BP values nor on the dose used .
When only ARB were considered , the drug used was a determinant for systolic BP reduction , whereas for diastolic BP the influence was on the BP reduction and the duration of the antihypertensive activity .
The dose used had a particular influence on the duration of the antihypertensive activity for both systolic and diastolic BP .
CONCLUSION Among the ARB , the influence is on duration more than on the magnitude of BP reduction .
Dose , therefore , is an important factor in the duration of antihypertensive activity
OBJECTIVE To perform a systematic review of the antihypertensive activity of the angiotensin II AT1 receptor antagonists ( ARB ) .